June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Eyedrop application of CLT-005, a Stat3 inhibitor, is efficacious in animal models of Wet and Dry Age-related Macular Degeneration
Author Affiliations & Notes
  • Rafal Farjo
    Charlesson, Oklahoma City, OK
  • Didier Nuno
    Charlesson, Oklahoma City, OK
  • Alexander Quiambao
    Charlesson, Oklahoma City, OK
  • Phillip Vanlandingham
    Charlesson, Oklahoma City, OK
  • Fadee Mondalek
    Charlesson, Oklahoma City, OK
  • Eric Phelps
    Charlesson, Oklahoma City, OK
  • Glenn Stoller
    SKS Ocular, Great Neck, NY
  • Drew Wassel
    Charlesson, Oklahoma City, OK
  • Footnotes
    Commercial Relationships Rafal Farjo, Charlesson LLC (E), EyeCRO LLC (E); Didier Nuno, Charlesson LLC (E), EyeCRO LLC (E); Alexander Quiambao, Charlesson, LLC (E), EyeCRO, LLC (E); Phillip Vanlandingham, Charlesson, LLC (E), EyeCRO (E); Fadee Mondalek, Charlesson, LLC (E), EyeCRO (E); Eric Phelps, Charlesson LLC (E), EyeCRO (E); Glenn Stoller, Lpath (C), Regeneron (F), Lpath (P), SKS (I); Drew Wassel, Charlesson LLC (E), EyeCRO (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1716. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Rafal Farjo, Didier Nuno, Alexander Quiambao, Phillip Vanlandingham, Fadee Mondalek, Eric Phelps, Glenn Stoller, Drew Wassel; Eyedrop application of CLT-005, a Stat3 inhibitor, is efficacious in animal models of Wet and Dry Age-related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1716.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

Activation of Stat3 in the posterior segment is associated with neovascular and inflammatory processes. We assessed the safety, ophthalmic distribution, and efficacy of CLT-005, a selective small molecule inhibitor of Stat3, after topical eyedrop administration to rabbit and rodent animal models.

 
Methods
 

A custom emulsion consisting of 1% CLT-005 was prepared and dosed daily at QID (9am, 12pm, 3pm, 6pm) for all experiments throughout the study duration. Dutch Belted rabbits were scored daily for tolerability/irritation, and the RPE/choroid was isolated for LC-MS/MS quantification of CLT-005 at Day 5. Brown Norway rats were induced by thermal laser to produce choroidal neovascular lesions on Day 1, and in-vivo fluorescein angiography was used to quantify lesion area on Day 22. The CEP Dry-AMD model (under license from SKS Ocular) was induced by immunization of C57Bl/6 mice with Carboxyethylpyrrole-Mouse Serum Albumin (CEP-MSA). At day 60, contrast sensitivity was evaluated with optokinetic tracking at a spatial frequency of 0.064 cycles/degree.

 
Results
 

Topical application of CLT-005 achieved mean drug levels in the RPE/Choroid of >2000 ng/g and did not result in any measurable hyperemia, chemosis, or discharge. In the laser-CNV model, treatment with topical CLT-005 or oral CLT-005 at 500 mg/kg in a soybean oil vehicle significantly reduced lesion size and late-stage leakage from lesions. In the CEP Dry-AMD model at Day 60, mean contrast sensitivity was significantly reduced to 0.0512 in CEP-MSA immunized mice as compared to 0.0841 in normal naïve controls. Daily eyedrop application of 1% CLT-005 prevented the loss of contrast sensitivity in CEP-MSA immunized mice and the mean was 0.0842, as compared to 0.054 in the vehicle control group. CLT-005 also significantly reduced inflammation in the posterior segment of CEP-MSA animals.

 
Conclusions
 

Eyedrop application of 1% CLT-005 delivers therapeutic amounts of drug to the RPE/choroid which can reduce neovascularization in the laser CNV model of wet AMD. Inhibition of Stat3 by CLT-005 also prevented the dramatic loss of contrast sensitivity in the CEP Dry-AMD model. These data support future clinical studies of topical CLT-005 as a standalone therapy or in conjunction with other intravitreal-based therapies to treat various forms of Age-related Macular Degeneration and Geographic Atrophy.

  
Keywords: 412 age-related macular degeneration • 478 contrast sensitivity • 609 neovascularization  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×